29.09.2010 • News

Bayer's Yasmin Patent Infringement Claim Dismissed

A U.S. judge on Tuesday dismissed Bayer’s patent lawsuit against Watson Pharmaceuticals and Novartis' Sandoz unit, which are seeking to market generic versions of Bayer's Yasmin birth control pills.

Bayer had alleged that the defendants infringed its patent by seeking U.S. approval to market generic versions of the oral contraceptive. The judge said that Bayer's patent does not claim a use for Yasmin that has been approved by the U.S. Food and Drug Administration.

The company's claim was dismissed "with prejudice," meaning it cannot be brought again.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read